Logo image
Back
Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy
Journal article   Peer reviewed

Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy

Tanja M Windegger, Janine English, Helen Weston, Karen Morwood, Mary Kynn, Paul Scuffham and Yoke-Lin Fung
Asia-Pacific Journal of Clinical Oncology, Vol.17(6), pp.546-554
2021
DOI: https://doi.org/10.1111/ajco.13515
PMID: 33460509
url
https://doi.org/10.1111/ajco.13515View
Published Version

Abstract

infection hypogammaglobulinemia hematological malignancy intravenous immunoglobulin subcutaneous immunoglobulin
Aim: To present findings from a longitudinal study on infection risk, mortality, and patient perspective of intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) treatment for patients with hypogammaglobulinemia secondary to hematological malignancy or its treatment (abbreviated as SID). Methods: Observational study period included final year of IVIg (13 patients) and of the first 3 years of SCIg (17 patients) with SID. Data were collected on clinical outcomes from medical records and patient perception via study specific questionnaire. Results: The median age was 63 years (53‐76 years), and for 82.4% of patients their hematological malignancy was in complete remission. The annual mean serum IgG trough levels remained stable over the 4 years and were 7.0 g/L (±2.77 g/L) with IVIg, and 8.0 g/L (±1.75 g/L), 8.7 g/L (±2.75 g/L), and 7.6 g/L (±2.89 g/L) (year 1, 2, and 3, respectively) with SCIg. While the annual infection rate was similar, the rate of hospitalization due to infection fluctuated, with 37%, 9%, 15%, and 32% in year 1, 2, 3, and 4 respectively. There were no systemic adverse events with IVIg or SCIg. Patients reported a strong preference for SCIg. One patient died due to progression of underlying disease and infection within the study period. Conclusion: SCIg was the preferred treatment mode over IVIg in our cohort, but both were well tolerated without any systemic adverse events in 4‐year follow up. The dosage and serum IgG levels were stable throughout. However, the number of infections requiring hospitalization fluctuated. It is anticipated that these findings encourage more hospitals to offer SCIg for SID patients.

Details

Metrics

59 Record Views
12 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Oncology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs from InCites

Logo image